VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

HOPA 2018 | Personalized therapy in leukemia: a case study

An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of relapse in patients. Here, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, discusses a case study in which the patient was identified with PD-L1 expression and a BRAF V600E mutation, and how these identifications helped improve the treatment outcome. Dr Kiel was speaking at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Transcript (edited for clarity)

I think we’ve progressed from an era of knowing diseases like chronic myeloid leukemia, where you have a specific Philadelphia chromosome positive driven disease which is present in 95% of the disease, it’s really looking at more patients on an individual basis and figuring out and what percentage of the time they might have this aberration.
So today I’ll be talking about some cases, one of which we have a patient who had PD-L1 expression indicative of a marker for immunotherapy, as well as a BRAF v600e DNA mutation which is typically seen in melanoma and other types of cancers and thyroid cancers...

I think we’ve progressed from an era of knowing diseases like chronic myeloid leukemia, where you have a specific Philadelphia chromosome positive driven disease which is present in 95% of the disease, it’s really looking at more patients on an individual basis and figuring out and what percentage of the time they might have this aberration.
So today I’ll be talking about some cases, one of which we have a patient who had PD-L1 expression indicative of a marker for immunotherapy, as well as a BRAF v600e DNA mutation which is typically seen in melanoma and other types of cancers and thyroid cancers.
But this is a patient from four years ago and essentially this patient was able to go on immunotherapy and achieve a complete response and was doing well for years, and normally this would have been somebody with widely spread metastatic, anaplastic disease, and survival would not have been estimated in years.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter